Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten J Postma

Showing results (131-140 of 485) with videos related to

Pageof 49
Sort By:
Japanese Journal of Clinical Oncology|January 3, 2017
Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysisDidik Setiawan, Jos Luttjeboer, Koen B Pouwels, et al.
Pharmacoeconomics|June 7, 2015
Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic AssessmentsNeily Zakiyah, Maarten J Postma, Philip N Baker, et al.
Pharmacoeconomics|June 11, 2011
Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidencePetros Pechlivanoglou, Robin De Vries, Simon M G J Daenen, et al.
Plos One|November 6, 2014
Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysisFolgerdiena M de Vries, Johan Kolthof, Maarten J Postma, et al.
Pharmacoeconomics|June 20, 2008
Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelinesStefan Vegter, Cornelis Boersma, Mark Rozenbaum, et al.
Vaccines|February 5, 2021
Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic ReviewTanja Fens, Pieter T de Boer, Eugène P van Puijenbroek, et al.
Pharmacoeconomics - Open|September 20, 2019
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The NetherlandsJudith J Gout-Zwart, Lisa A de Jong, Lisanne Saptenno, et al.
Pharmacoeconomics|September 13, 2005
The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccineRobert Welte, Caroline L Trotter, W John Edmunds, et al.
Clinical Therapeutics|August 19, 2007
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The NetherlandsCornelis Boersma, George W Carides, Jarir Atthobari, et al.
Clinical Therapeutics|August 24, 2010
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the NetherlandsMark H Rozenbaum, Eelko Hak, Tjip S van der Werf, et al.
Pageof 49

Showing results (131-140 of 485) with videos related to

Sort By:
Pageof 49
Japanese Journal of Clinical Oncology|January 3, 2017
Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysisDidik Setiawan, Jos Luttjeboer, Koen B Pouwels, et al.
Pharmacoeconomics|June 7, 2015
Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic AssessmentsNeily Zakiyah, Maarten J Postma, Philip N Baker, et al.
Pharmacoeconomics|June 11, 2011
Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidencePetros Pechlivanoglou, Robin De Vries, Simon M G J Daenen, et al.
Plos One|November 6, 2014
Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysisFolgerdiena M de Vries, Johan Kolthof, Maarten J Postma, et al.
Pharmacoeconomics|June 20, 2008
Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelinesStefan Vegter, Cornelis Boersma, Mark Rozenbaum, et al.
Vaccines|February 5, 2021
Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic ReviewTanja Fens, Pieter T de Boer, Eugène P van Puijenbroek, et al.
Pharmacoeconomics - Open|September 20, 2019
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The NetherlandsJudith J Gout-Zwart, Lisa A de Jong, Lisanne Saptenno, et al.
Pharmacoeconomics|September 13, 2005
The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccineRobert Welte, Caroline L Trotter, W John Edmunds, et al.
Clinical Therapeutics|August 19, 2007
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The NetherlandsCornelis Boersma, George W Carides, Jarir Atthobari, et al.
Clinical Therapeutics|August 24, 2010
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the NetherlandsMark H Rozenbaum, Eelko Hak, Tjip S van der Werf, et al.
Pageof 49